Charles Schwab
BNGO icon

Charles Schwab’s Bionano Genomics BNGO Stock Holding History

Charles Schwab’s Portfolio BNGO Stock Details BNGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-467
Closed -$19K – 3512
2024
Q2 		$19K Hold
467
– – ﹤0.01% 3593
2024
Q1 		$31.1K Hold
467
– – ﹤0.01% 3408
2023
Q4 		$52.9K Hold
467
– – ﹤0.01% 3399
2023
Q3 		$84.8K Sell
467
-1,699
-78% -$445K ﹤0.01% 3368
2023
Q2 		$793K Sell
2,166
-1,480
-41% -$668K ﹤0.01% 2844
2023
Q1 		$2.43M Sell
3,646
-20
-0.5% -$17.8K ﹤0.01% 2471
2022
Q4 		$3.21M Buy
3,666
+133
+4% +$167K ﹤0.01% 2409
2022
Q3 		$3.88M Buy
3,533
+60
+2% +$79.3K ﹤0.01% 2354
2022
Q2 		$2.88M Sell
3,473
-41
-1% -$42.2K ﹤0.01% 2437
2022
Q1 		$5.44M Buy
3,514
+99
+3% +$134K ﹤0.01% 2239
2021
Q4 		$6.13M Buy
3,415
+178
+5% +$476K ﹤0.01% 2246
2021
Q3 		$10.7M Buy
3,237
+2,069
+177% +$7.24M ﹤0.01% 1971
2021
Q2 		$5.14M Buy
1,168
+1,057
+952% +$4.17M ﹤0.01% 2343
2021
Q1 		$538K Buy
+111
New +$626K ﹤0.01% 3054

Other funds holding BNGO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
CAM
Carret Asset Management New York $1.14B AUM 35.33% 1-Year Est. Return

Charles Schwab's BNGO Position: Q3 2024 in Review

Charles Schwab sold out of Bionano Genomics (BNGO) in Q3 2024, closing a stake of 467 shares — an estimated $19K sold.

Charles Schwab first reported a position in BNGO in Q1 2021 and held it in 14 quarters. The position peaked at $10.7M in Q3 2021. 48 funds tracked by Wall St. Rank hold BNGO as of Q3 2024.

  • Charles Schwab reported no remaining Bionano Genomics position as of Q3 2024 after selling out during the quarter.
  • Charles Schwab sold 467 Bionano Genomics shares in Q3 2024, an estimated $19K.
  • Charles Schwab first reported a position in Bionano Genomics in Q1 2021 and held it in 14 quarters.
  • Charles Schwab's Bionano Genomics position peaked at $10.7M in Q3 2021.
  • 48 funds tracked by Wall St. Rank held Bionano Genomics as of Q3 2024.

Based on Charles Schwab's 13F filing for Q3 2024, filed 12 Nov 2024.